Identification of KIF20A as a tumor biomarker and forwarder of clear cell renal cell carcinoma  

作　　者：Wen Xiao Ke Chen Hua-Geng Liang Xiao-Ping Zhang 

机构地区：[1]Department of Urology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430022,China

出　　处：《Chinese Medical Journal》2021年第17期2137-2139,共3页中华医学杂志（英文版）

基　　金：This project was supported by grants from the National Natural Science Foundation of China(No.81902588);the National Key Scientific Instrument Development Project(No.81927807).

摘　　要：To the Editor:Renal cell carcinoma(RCC)is one of the top 10 major cancer types in adults.Current research shows that clear cell renal cell carcinoma(ccRCC)remains a deadly tumor disease and is associated with most cancerrelated deaths.[1]Timely diagnosis is extremely important for the treatment of tumor patients.Adjusting the treatment plan based on the results of clinical diagnostic markers has a positive effect on patient prognosis.There is still a high risk of local recurrence or distant metastasis after nephrectomy.Tyrosine kinase inhibitor(TKI)has shown encouraging efficacy in advanced ccRCC patients.[2]Unfortunately,TKI resistance still develops and can lead to poor progression in cancer.[3]Thus,there is an urgent need to explore more effective prognostic biomarkers and to identify novel drug targets for ccRCC therapies.

关 键 词：DIAGNOSIS METASTASIS TREATMENT 

分 类 号：R737.11[医药卫生—肿瘤]